INTRA CELLULAR

ITCI NASDAQ
12.90
-1.19
-8.45%
盘后: 13.10 +0.2 +1.55% 17:31 06/20 EDT
开盘
14.31
昨收
14.09
最高
14.34
最低
12.45
成交量
110.58万
成交均量(3M)
37.46万
52周最高
23.62
52周最低
10.21
换手率
2.01%
市值
7.11亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供INTRA CELLULAR ITCI股票价格,INTRA CELLULAR股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).
展开 >

最近浏览

名称
价格
涨跌幅